Cyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded to Hold by StockNews.com

StockNews.com upgraded shares of Cyclacel Pharmaceuticals (NASDAQ:CYCCFree Report) from a sell rating to a hold rating in a report released on Tuesday.

Other equities analysts have also recently issued reports about the company. Roth Mkm upped their price objective on Cyclacel Pharmaceuticals from $16.00 to $21.00 and gave the stock a buy rating in a report on Tuesday, December 19th. Brookline Capital Management cut Cyclacel Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, December 19th.

Get Our Latest Research Report on Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Stock Down 8.9 %

CYCC stock opened at $1.95 on Tuesday. The stock has a 50-day simple moving average of $2.43 and a two-hundred day simple moving average of $4.28. Cyclacel Pharmaceuticals has a twelve month low of $1.82 and a twelve month high of $13.20. The firm has a market capitalization of $1.64 million, a PE ratio of -0.07 and a beta of 0.56.

Institutional Investors Weigh In On Cyclacel Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC boosted its stake in shares of Cyclacel Pharmaceuticals by 6.5% during the 4th quarter. Millennium Management LLC now owns 208,062 shares of the biotechnology company’s stock worth $139,000 after acquiring an additional 12,617 shares during the last quarter. Virtu Financial LLC purchased a new stake in Cyclacel Pharmaceuticals in the 2nd quarter worth about $33,000. HRT Financial LP purchased a new position in Cyclacel Pharmaceuticals in the 4th quarter worth about $27,000. Renaissance Technologies LLC bought a new stake in shares of Cyclacel Pharmaceuticals in the second quarter valued at about $68,000. Finally, Two Sigma Investments LP bought a new position in shares of Cyclacel Pharmaceuticals in the 3rd quarter worth $98,000. Institutional investors own 23.58% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

(Get Free Report)

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.

Further Reading

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.